Progressive Familial Intrahepatic Cholestasis (PFIC) Market to Register Immense Growth During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Vivet Therapeutics (VTX-803), Mirum Pharmaceuticals (Maralixibat)

As per DelveInsight, the Progressive Familial Intrahepatic Cholestasis Market is anticipated to evolve immensely in the coming years owing to the rise in number of prevalent cases and the launch of new therapies in the market.

DelveInsight's "Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Progressive Familial Intrahepatic Cholestasis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Progressive Familial Intrahepatic Cholestasis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Progressive Familial Intrahepatic Cholestasis (PFIC): An Overview
According to the National Institute of Health (NIH), Progressive Familial Intrahepatic Cholestasis (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure in which liver cells are unable to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.

There are mainly three types of PFIC which occur due to mutations in the genes, such as ATP8B1, ABCB11, and ABCB4, which result in development of PFIC1, PFIC2, and PFIC3 respectively. Mutations in these genes lead to a failure of proteins to function normally and thereby cause PFIC in many patients. PFIC usually appears in the first months of life in patients with PFIC1 resulting in characterized by recurrent episodes of jaundice, which become permanent later in the course of the disease. In case of PFIC2, the initial presentation and the evolution seem to become more severe, resulting into permanent jaundice from the first months of life and the rapid appearance of liver failure within the first years of life.

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Key Facts
• The United Kingdom-based study titled "Systematic review of progressive familial intrahepatic cholestasis" conducted by Baker et al. found that the incidence of intrahepatic cholestasis was 1 per 18,000 live births. The researchers also referred to a study in which infants and children (2-18 years) with cholestasis were 12-13% with genetically diagnosed PFIC.
• According to a French study by Davit-Spraul et al., titled as "Progressive familial intrahepatic cholestasis", highlighted that the estimated incidence varies between 1 per 50,000 and 1 per 100,000 births in the PFIC patients. It was also found that PFIC1 and PFIC2 represented two out of three cases of total PFIC, whereas PFIC3 was one case per three cases.

Discover How Progressive Familial Intrahepatic Cholestasis Market Will Grow by 2032:
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Progressive Familial Intrahepatic Cholestasis (PFIC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Progressive Familial Intrahepatic Cholestasis therapies in the market. It also provides a detailed assessment of the Progressive Familial Intrahepatic Cholestasis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Progressive Familial Intrahepatic Cholestasis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Progressive Familial Intrahepatic Cholestasis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Progressive Familial Intrahepatic Cholestasis Epidemiology Segmented as -
• Prevalent Population of PFIC in the 7MM [2019-2032]
• Type-specific Prevalent Population of PFIC in the 7MM [2019-2032]
• Diagnosed and Treatable Cases of PFIC in the 7MM [2019-2032]

Get Key Insights Into the Evolving Progressive Familial Intrahepatic Cholestasis Epidemiology Trends @
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Progressive Familial Intrahepatic Cholestasis (PFIC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Familial Intrahepatic Cholestasis market or expected to be launched during the study period. The analysis covers the market share by Progressive Familial Intrahepatic Cholestasis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Progressive Familial Intrahepatic Cholestasis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Progressive Familial Intrahepatic Cholestasis (PFIC) Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Currently, Mirum Pharmaceuticals is leading the therapeutics market with its Progressive Familial Intrahepatic Cholestasis (PFIC) drug candidates in the most advanced stage of clinical development.

Leading Companies in the Progressive Familial Intrahepatic Cholestasis (PFIC) Therapeutics Market Include
• Mirum Pharmaceuticals
• Vivet Therapeutics
And Many Others

Emerging and Marketed Progressive Familial Intrahepatic Cholestasis (PFIC) Therapies Covered in the Report Include
• VTX-803: Vivet Therapeutics
• Maralixibat: Mirum Pharmaceuticals
And Many More

Learn More About the Emerging Therapies & Key Companies in the Progressive Familial Intrahepatic Cholestasis Therapeutics Market:
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Progressive Familial Intrahepatic Cholestasis Competitive Intelligence Analysis
4. Progressive Familial Intrahepatic Cholestasis Market Overview at a Glance
5. Progressive Familial Intrahepatic Cholestasis Background and Overview
6. Progressive Familial Intrahepatic Cholestasis Patient Journey
7. Progressive Familial Intrahepatic Cholestasis Epidemiology and Patient Population
8. Progressive Familial Intrahepatic Cholestasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Familial Intrahepatic Cholestasis Unmet Needs
10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis Treatment
11. Progressive Familial Intrahepatic Cholestasis Marketed Products
12. Progressive Familial Intrahepatic Cholestasis Emerging Therapies
13. Progressive Familial Intrahepatic Cholestasis Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Familial Intrahepatic Cholestasis Market Outlook (7 major markets)
16. Progressive Familial Intrahepatic Cholestasis Access and Reimbursement Overview
17. KOL Views on the Progressive Familial Intrahepatic Cholestasis Market.
18. Progressive Familial Intrahepatic Cholestasis Market Drivers
19. Progressive Familial Intrahepatic Cholestasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Acute Ocular Pain Market
https://www.delveinsight.com/report-store/acute-ocular-pain-market

Adenoid Cystic Carcinoma Market
https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market

Frontotemporal Dementia Market
https://www.delveinsight.com/report-store/frontotemporal-dementia-market

Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market

Dense Deposit Disease Market
https://www.delveinsight.com/report-store/dense-deposit-disease-market

High-Grade Glioma Market
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market

Implantable Infusion Pumps Global Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market

Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market

Post-Polycythemia Vera Myelofibrosis Market
https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-market

Postmyocardial Infarction Syndrome Market
https://www.delveinsight.com/report-store/postmyocardial-infarction-syndrome-market

Acute ischemic stroke (AIS) Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market

Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market

Conductive Hearing Loss Market
https://www.delveinsight.com/report-store/conductive-hearing-loss-market

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

Ductal Carcinoma in Situ Market
https://www.delveinsight.com/report-store/ductal-carcinoma-in-situ-market

Electroencephelographs (EEG) Pipeline Insight
https://www.delveinsight.com/report-store/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape

Encephalomyelitis Market
https://www.delveinsight.com/report-store/encephalomyelitis-market
Graves Ophthalmopathy Market
https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

Graves Orbitopathy Market
https://www.delveinsight.com/report-store/graves-orbitopathy-market

Hemophagocytic Lymphohistiocytosis Market
https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/recurrent-head-and-neck-cancer-squamous-cell-carcinoma-market

Tenosynovitis Market
https://www.delveinsight.com/report-store/tenosynovitis-market

Urticaria Or Hives Market
https://www.delveinsight.com/report-store/urticaria-or-hives-market

Dermal Regeneration Matrix Market
https://www.delveinsight.com/report-store/dermal-regeneration-matrix-market

Glioma Market
https://www.delveinsight.com/report-store/glioma-market

Angelman Syndrome Market
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast

Chronic Pancreatitis (CP) Market
https://www.delveinsight.com/report-store/chronic-pancreatitis-market

Follicular Lymphoma Market
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights

Hereditary Spastic Paraplegias Market
https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market

Decompensated Cirrhosis Market
https://www.delveinsight.com/report-store/decompensated-cirrhosis-market

Hepatitis D Market
https://www.delveinsight.com/report-store/hepatitis-d-market

Nontuberculous Mycobacterial (NTM) Infections Market
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.